Novartis Ag

Frederic Zecri

Jun Yuan

Hongjuan Zhao

Philipp Grosche

Thomas Zabawa

Aimee Richardson Usera

Aaron Kanter

Andrew John Geall

Kevin Thomas Love

Luis Brito

Delai Chen

Kayo Yasoshima

Gabriel Grant Gamber

Changgang Lou

Pascal Furet

Ian Lewis

Nicolas Soldermann

Alexander Baxter Smith

John Louis Diener

Giorgio Caravatti

Qi-Ying Hu

Konstanze Hurth

Rainer Albert

Hidetomo Imase

Nicola Tufilli

Xin Chen

Gregory Raymond Bebernitz

David Thomas Parker

David Weninger Barnes

Sylvie Chamoin

Sarah Williams

Scott Louis Cohen

Qian Liu

Andrei Alexandrovich Golosov

Frank Stowasser

Nigel Graham Cooke

Shari Lynn Caplan

Ken Yamada

Henrik Moebitz

Eric Francotte

Rui Zheng

Louise Clare Kirman

Anette Von Matt

Carla Guimaraes

Tajesh Jayprakash Patel

Gregory John Hollingworth

Christina Hebach

Frédéric Stauffer

Lewis Whitehead

Yu Gai

Ming Qian

Justin Yik Ching Mao

Alexandra Marshall Bruce

Romain Wolf

Sejal Patel

Karen Kammertoens

David Barnes-Seeman

Justin Mao

Tyler Harrison

Rohit Duvadie

Klemens Hogenauer

Christian Gampe

James Roache

Amy White

Ross Strang

Christoph Kalis

Yizong Zhou

Markus Zollinger

Paulo Antonio Fernandes Gomes Dos Santos

Robert Francis Day

Klemens Hoegenauer

Chikwendu Ibebunjo

Nadege Graveleau

Carla Giumaraes

Emma Cody

Philippr Grosche

Jay Larrow

Xuchun Zheng

Jiong Ye

Yiping Ding

Nicola Tuffilli

Eric Peters

Avirup Bose

Paulo Fernandes Gomes Dos Santos

Frederic Stauffer

Alokesh Duttaroy

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:

Fatty acids and their use in conjugation to biomolecules

The disclosure relates to nucleic acids that contain modifications at the 5'-end, 3&#x2032;-end or 5&#x2032;-end and 3&#x2032;-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.

3' end caps, 5&#x2032; end caps and combinations thereof for therapeutic RNA

This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R-R, L, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Lipids and lipid compositions for the delivery of active agents

This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R-R, n, p, Land Lare defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: 

This invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R-R, n, p, Land Lare defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues. 

This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R-R, n and p are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues. 

The invention relates to novel compositions comprising modified apelin-13 peptide sequences designed to treat cardiovascular disease in subjects to whom they are administered, and which exhibit greater resistance to degradation, and equivalent or greater bioactivity than their wild type counterparts. The invention also relates to methods of making said compositions and using said compositions as pharmaceutically active agents to treat cardiovascular disease.

Synthetic linear apelin mimetics for the treatment of heart failure

The invention provides a synthetic polypeptide of Formula I': 

Synthetic apelin mimetics for the treatment of heart failure

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

Use of inhibitors of the activity or function of PI3K

The invention provides a conjugate, or a pharmaceutically acceptable salt thereof, comprising a synthetic polypeptide of Formula I:Q-R-P-R-L-C*-H-K-G-P-(Nle)-C*-F&#x2003;&#x2003;(I)or a amide or ester thereof; and a fatty acid selected from: wherein said fatty acid is covalently linked to the N-terminus of the peptide via one of its carboxylic acid functionality, optionally via a polyethylene glycol linker; and wherein the two cysteine amino acids labeled with '*' form a disulfide bond between the thiol functionalities of their side chain. The conjugates are agonist of the APJ receptor. The invention also relates to a method for manufacturing the conjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Synthetic apelin fatty acid conjugates with improved half-life

The invention provides a synthetic polypeptide of Formula I (SEQ ID NO: 1):X1-R-X3-R-L-X6-X7-K-X9-P-X11-X12-X13&#x2003;&#x2003;I

Cyclic apelin derivatives for the treatment of heart failure

Growing community of inventors

Brookline, MA, United States of America

Frederic Zecri